Free shipping on all orders over $ 500

Tocilizumab

Cat. No. M6223
Tocilizumab Structure
Synonym:

MRA

Size Price Availability Quantity
5mg USD 750 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

In vitro: Tocilizumab inhibits the binding of IL-6 to its receptors, and thus reduces the cytokines pro-inflammatory activity by competing for both the soluble and membrane-bound forms of the human IL-6 receptor. The inhibitory profile of anti-IL-6R mAb Tocilizumab is independent of membrane-bound IL-6R expression. Tocilizumab has anticancer potency via apoptosis induction as an agonistic IL-6R regulator. It has also been demonstrated that tocilizumab has an anti-proliferative effect on glioma cells via inhibition of the JAK-STAT3 pathway. Tocilizumab exhibits a significant growth inhibition in NSCLC cells (H460, A549, H1299 and H358), with proliferation significantly decreased by approximately 40% in A549 cells. Tocilizumab does not alter the levels of the ERK1/2, STAT3, NFκB and phosphorylated ERK1/2 and STAT3 proteins, but this antibody does considerably increase the expression of phosphorylated NFκB in NSCLC cells. Tocilizumab significantly inhibits expression of both IL-8 and MMP-9, known as the major angiogenic factors.

In vivo: A series of clinical studies has shown that inhibition of IL-6 signaling by tocilizumab is therapeutically effective in rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, and Crohn's disease. In all of these diseases, tocilizumab ameliorates inflammatory manifestations, and normalizes acute phase protein levels. Tocilizumab as a monotherapy and in combination, such as with methotrexate in case of rheumatoid arthritis, seems to be well tolerated. Tocilizumab markedly decreases the number of invaded capillary vessels in tumors. In addition, tocilizumab shows almost no effect on mitogenic rate and apoptosis of tumor cells.

Protocol
Cell Experiment
Cell lines non-small cell lung cancer (NSCLC) cells (A549, H460, H358 and H1299 cells)
Preparation method Ten microliters of tocilizumab, MTX or 5-FU are added to 96-well plates containing 104 cells per well in 100 µl medium. The final concentrations of tocilizumab are 10, 100 and 1000 ng/ml. The final concentrations of MTX and 5-FU are 50 and 25 µg/ml, respectively. Following a 24-h incubation, WST-1 solution is added, and the optical density is analyzed at reference wavelengths of 450 and 620 nm.
Concentrations 10, 100 and 1000 ng/ml
Incubation time 24 h
Animal Experiment
Animal models Male CB17/ICR-scid/scid mice (SCID mice)
Formulation PBS
Dosages 100 μg
Administration i.p.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight
Formula
CAS Number
Purity >98%
Solubility
Storage at -20°C
References

Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab.
Berti A, et al. Semin Arthritis Rheum. 2015 Aug;45(1):48-54. PMID: 25841802.

Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M, et al. Int Rev Immunol. 2015 May;34(3):265-79. PMID: 25099958.

Related Products
LY2334737

LY2334737 is an orally available valproic acid ester of gemcitabine, a broad-spectrum antimetabolite with antineoplastic activity.

TUG-891

TUG-891 is a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120).

GSK2981278

GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).

EXP-3174

EXP-3174 is a potent AT1 antagonist with Kis of 0.57 and 0.67 nM for rat and human forms, respectively.

NAV-2729

NAV-2729 is a selective ARF6 inhibitor with IC50 value of 1.0 μM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Tocilizumab, MRA supplier, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.